Cheng Susan, Shah Svati H, Corwin Elizabeth J, Fiehn Oliver, Fitzgerald Robert L, Gerszten Robert E, Illig Thomas, Rhee Eugene P, Srinivas Pothur R, Wang Thomas J, Jain Mohit
Circ Cardiovasc Genet. 2017 Apr;10(2). doi: 10.1161/HCG.0000000000000032.
Through the measure of thousands of small-molecule metabolites in diverse biological systems, metabolomics now offers the potential for new insights into the factors that contribute to complex human diseases such as cardiovascular disease. Targeted metabolomics methods have already identified new molecular markers and metabolomic signatures of cardiovascular disease risk (including branched-chain amino acids, select unsaturated lipid species, and trimethylamine--oxide), thus in effect linking diverse exposures such as those from dietary intake and the microbiota with cardiometabolic traits. As technologies for metabolomics continue to evolve, the depth and breadth of small-molecule metabolite profiling in complex systems continue to advance rapidly, along with prospects for ongoing discovery. Current challenges facing the field of metabolomics include scaling throughput and technical capacity for metabolomics approaches, bioinformatic and chemoinformatic tools for handling large-scale metabolomics data, methods for elucidating the biochemical structure and function of novel metabolites, and strategies for determining the true clinical relevance of metabolites observed in association with cardiovascular disease outcomes. Progress made in addressing these challenges will allow metabolomics the potential to substantially affect diagnostics and therapeutics in cardiovascular medicine.
通过对多种生物系统中数千种小分子代谢物的测量,代谢组学现在为深入了解导致心血管疾病等复杂人类疾病的因素提供了新的可能性。靶向代谢组学方法已经确定了心血管疾病风险的新分子标志物和代谢组学特征(包括支链氨基酸、特定不饱和脂质种类和氧化三甲胺),从而实际上将饮食摄入和微生物群等不同暴露与心脏代谢特征联系起来。随着代谢组学技术不断发展,复杂系统中小分子代谢物谱分析的深度和广度也在迅速推进,持续发现的前景也随之增加。代谢组学领域目前面临的挑战包括扩大代谢组学方法的通量和技术能力、处理大规模代谢组学数据的生物信息学和化学信息学工具、阐明新代谢物生化结构和功能的方法,以及确定与心血管疾病结果相关的代谢物真正临床相关性的策略。在应对这些挑战方面取得的进展将使代谢组学有可能对心血管医学的诊断和治疗产生重大影响。